- Although Alzheimer’s disease is the most common form of dementia, there is still no cure for the disease.
- New disease-modifying drugs have shown potential, but there are concerns about side effects of these treatments.
- In the search for new therapies, a study has developed a molecule that restores lost cognitive function in mice.
- The study authors suggest that, if similar results are seen in people, this could be the basis of a novel treatment for Alzheimer’s.
Some
- memory loss, especially taking in and remembering new information
- cognitive deficits, such as difficulty with reasoning, complex tasks and judgment
- recognising familiar objects and people
- problems with spatial awareness
- difficulties with speaking, reading and writing
- personality or behavior changes.
Newer monoclonal antibody drugs that clear the
Now, a new study has identified and synthesized a molecule that restores cognitive function in Alzheimer’s disease model mice by increasing
The study, by researchers from The University of California, Los Angeles (UCLA), is published in Proceedings of the National Academy of Sciences (PNAS).
Stefania Forner, PhD, Alzheimer’s Association director of medical and scientific relations, not involved in this research, told Medical News Today:
“It is an exciting time in Alzheimer’s disease and dementia research with hundreds of potential therapies being tested at various stages of the research process, and many more being developed. This study, using a mouse model of Alzheimer’s disease, explores a new approach to improving brain function related to cognition and memory.”
Gamma oscillations are high-frequency waves in the brain that play a role in many cognitive processes and
Even in the early stages of Alzheimer’s disease, these oscillations are reduced, and
Some studies have improved cognitive ability in people with mild to moderate Alzheimer’s disease using repetitive transcranial magnetic stimulation (rTMS), which has been shown to
In this study, the researchers aimed to enhance gamma oscillations by another method — using a molecule that targeted fast-firing nerve cells that are critical in generating gamma oscillations.
The molecule they identified — DDL-920 — acted on chemical receptors in these nerve cells that respond to the inhibitory chemical messenger known as
Forner told MNT: “The study tests a small molecule called DDL-920, which boosts these gamma oscillations. Unlike current FDA-approved treatments that focus on removing beta-amyloid plaques, DDL-920 targets brain circuitry in a different way.”
“While this approach offers a fresh perspective on enhancing cognitive function and memory in Alzheimer’s, it’s important to note that the research is still in the early stages using mouse models,” she noted.
Having established that DDL-920 increased gamma oscillations, the researchers then used an Alzheimer’s disease mouse model to determine whether this resulted in improved cognitive function.
They gave DDL-920 orally twice a day to 3-month old Alzheimer’s disease model mice. As a comparison, a similar number of AD model mice and wild-type mice were given a vehicle (inactive compound).
The mice were then tested in a
Following treatment, the Alzheimer’s disease model mice could recall the location of the escape hole at the same rate as the wild-type mice. Untreated Alzheimer’s disease model mice took significantly longer.
Emer MacSweeney, MD, CEO and Consultant Neuroradiologist at Re:Cognition Health, also not involved in this research, explained that “[t]he study suggests that DDL-920 enhances memory and cognition by increasing gamma-oscillation power without affecting other brain functions or causing side effects.”
However, she added a note of caution, pointing out that, “[s]ince the findings are based on a mouse model, further research is needed to evaluate the efficacy and safety of DDL-920 in humans.”
The study authors suggest that if similar effects were seen in people, DDL-920 could form the basis of new treatments to revitalize memory and cognition in Alzheimer’s disease.
“DDL-920 operates differently from monoclonal antibody (MAB) treatments like lecanemab, which target amyloid-beta plaques directly. Instead, DDL-920 enhances γ-oscillations, which may improve cognitive function, indirectly. This approach could have potential, especially if combined with MAB treatments, offering a complementary mechanism that targets neural activity and cognitive processes rather than amyloid burden alone. This could be particularly beneficial for patients who might not respond fully to amyloid-targeting therapies.”
– Emer MacSweeney, MD
Forner welcomed the results as “intriguing,” but emphasized that animal models, while similar to the progression of Alzheimer’s disease in people, cannot exactly replicate the condition. She also highlighted the importance of research into potential new treatments:
“Treatments that target Alzheimer’s from all angles and all stages of the disease are essential, and that’s why strategic research funding that works to diversify the therapies in the pipeline is so important. All evidence-based paths to treatment of Alzheimer’s and all other dementia should be explored,” she told us.
“The Alzheimer’s Association envisions a future where there are many treatments available that address these diseases in multiple ways, and can be combined into powerful combination therapies, most likely in conjunction with brain-Healthy lifestyle guidance,” she added.
